Xing P - Search Results

1

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma.

Sun D, Hou H, Feng F, Wu W, Tan J, Xie T, Liu J, Wang J, Qian H, Li J, Xing P. Sun D, et al. Among authors: xing p. Exp Hematol Oncol. 2025 Jan 7;14(1):3. doi: 10.1186/s40164-024-00594-4. Exp Hematol Oncol. 2025. PMID: 39773749 Free PMC article.

2

[Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events].

Xie T, Wang S, Xing P. Xie T, et al. Among authors: xing p. Zhongguo Fei Ai Za Zhi. 2020 Jul 20;23(7):603-608. doi: 10.3779/j.issn.1009-3419.2020.102.17. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32702794 Free PMC article. Review. Chinese.

3

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.

Sun D, Teng F, Xing P, Li J. Sun D, et al. Among authors: xing p. Mol Med. 2021 Oct 29;27(1):138. doi: 10.1186/s10020-021-00400-5. Mol Med. 2021. PMID: 34715776 Free PMC article. Review.

4

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report.

Li Y, Xu Z, Xie T, Xing P, Ying J, Li J. Li Y, et al. Among authors: xing p. Front Oncol. 2022 Aug 11;12:937282. doi: 10.3389/fonc.2022.937282. eCollection 2022. Front Oncol. 2022. PMID: 36033496 Free PMC article.

5

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.

Sun D, Qian H, Wang J, Xie T, Teng F, Li J, Xing P. Sun D, et al. Among authors: xing p. Cell Commun Signal. 2022 Oct 13;20(1):156. doi: 10.1186/s12964-022-00958-5. Cell Commun Signal. 2022. PMID: 36229854 Free PMC article.

6

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.

Sun D, Feng F, Teng F, Xie T, Wang J, Xing P, Qian H, Li J. Sun D, et al. Among authors: xing p. Cell Commun Signal. 2023 Mar 3;21(1):48. doi: 10.1186/s12964-023-01065-9. Cell Commun Signal. 2023. PMID: 36869329 Free PMC article.

7

PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells.

Sun D, Xing P, Li J. Sun D, et al. Among authors: xing p. Cancer Innov. 2022 Dec 7;1(4):348-349. doi: 10.1002/cai2.39. eCollection 2022 Dec. Cancer Innov. 2022. PMID: 38089081 Free PMC article.

8

Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy.

Sun D, Qian H, Li J, Xing P. Sun D, et al. Among authors: xing p. J Biomed Sci. 2024 Jan 29;31(1):17. doi: 10.1186/s12929-024-01004-x. J Biomed Sci. 2024. PMID: 38281981 Free PMC article. Review.

9

Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review).

Liu JY, Wang SZ, Yuan HQ, Li JL, Xing PY. Liu JY, et al. Among authors: xing py. Oncol Lett. 2024 Dec 20;29(3):109. doi: 10.3892/ol.2024.14855. eCollection 2025 Mar. Oncol Lett. 2024. PMID: 39776649 Free PMC article. Review.

10

[Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].

Xie T, Li Y, Xing P. Xie T, et al. Among authors: xing p. Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):701-709. doi: 10.3779/j.issn.1009-3419.2020.102.22. Epub 2020 Aug 6. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32758349 Free PMC article. Review. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

838 results

Search Page

Filters